Urothelial Carcinoma

Role of FGFR3 in Urothelial Carcinoma

Background and Objective: This study was undertaken to analyze the immunohistochemical expression of fibroblast growth factor receptor (FGFR3) in urothelial carcinoma and correlate its expression with the pathological stage, recurrence and other clinicopathological parameters. Material and Methods: A retrospective study was undertaken on paraffin blocks o...

Urothelial Carcinoma

1Department of Pathology, College of Medicine, National Cheng Kung University, No.1 University Road, Tainan City 701, Taiwan 2Leeds Institute for Molecular Medicine, Section of Experimental Oncology, Cancer Research UK Clinical Centre, St Jame’s University Hospital, Beckett Street, Leeds LS9 7TF, UK 3 Johns Hopkins Medical Institutions, The James Buchanan Brady Urological Institute, 600 N. Wolf...

Urothelial Cell Carcinoma

Targeting Hsp90 in urothelial carcinoma

Urothelial carcinoma, or transitional cell carcinoma, is the most common urologic malignancy that carries significant morbidity, mortality, recurrence risk and associated health care costs. Despite use of current chemotherapies and immunotherapies, long-term remission in patients with muscle-invasive or metastatic disease remains low, and disease recurrence is common. The molecular chaperone He...

Microcystic Variant of Urothelial Carcinoma

Background. Microcystic variant of urothelial carcinoma is one of the new variants of urothelial carcinoma that was added to the WHO classification in 2004. Aims. To review the literature on microcystic variant of urothelial carcinoma. Methods. Various internet search engines were used to identify reported cases of the tumour. Results. Microscopic features of the tumour include: (i) Conspicuous...